KZIA Positive Overall Survival in Glioblastoma Study Kazia expects to present further data in 2H CY2020 Sales in excess of US$ 1 billion per annum treatment for glioblastoma
I'm seeing the same thing with my charts. Very interested. Only drawback is their cash position. Any thoughts?
Time_Oracle
⋅
@BarillaElmo, apart those in the comment section from my dd,looks like a good company.be careful.I am seeing a lot of companies doing offerings these times.